Haas Jason insider trades
Haas Jason has filed 18 Form 4s with the SEC that we hold, for SYRS (Chief Financial Officer), Ligand Pharmaceuticals INC (LGND) (Director) and Odyssey Therapeutics, Inc. (ODTX) (Chief Financial Officer). Across all of them we count 4 purchases worth $181.5K and 4 sales worth $3.8M reported on Form 4. In the last 12 months: 1 purchase ($20.0K) and 3 sales ($3.7M). The largest single trade was a sale of 7,138 shares of Ligand Pharmaceuticals INC worth $2.1M, dated 2026-08-12. The first filing on our record is dated 2021-10-13 and the latest 2026-08-14.
SYRS
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-09-10 | P, purchase reported on Form 4 | 35,363 | $54.8K | 2024-09-12 |
| 2024-09-11 | P, purchase reported on Form 4 | 19,293 | $30.5K | 2024-09-12 |
| 2024-09-12 | P, purchase reported on Form 4 | 45,344 | $76.2K | 2024-09-12 |
| 2024-11-18 | S, sale reported on Form 4 | 137,803 | $28.9K | 2024-11-20 |
Ligand Pharmaceuticals INC (LGND)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-06-12 | S, sale reported on Form 4 | 3,461 | $886.3K | 2026-06-15 |
| 2026-06-12 | S, sale reported on Form 4 | 3,000 | $765.0K | 2026-06-15 |
| 2026-08-12 | S, sale reported on Form 4 | 7,138 | $2.1M | 2026-08-14 |
Odyssey Therapeutics, Inc. (ODTX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-05-08 | P, purchase reported on Form 4 | 1,000 | $20.0K | 2026-05-11 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1883821) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms